Changing Epidemiology of Hepatitis A and Hepatitis E Viruses in China, 1990–2014 by Cowling, BJ et al.
Title Changing Epidemiology of Hepatitis A and Hepatitis E Viruses inChina, 1990–2014
Author(s) REN, X; Wu, P; Wang, L; Geng, M; Zeng, L; Zhang, J; Xia, N; Lai,S; Dalton, H; Cowling, BJ; Yu, H
Citation Emerging Infectious Diseases, 2017, v. 23, p. 276-279
Issued Date 2017
URL http://hdl.handle.net/10722/244559
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
276 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 2, February 2017
DISPATCHES
Xiang Ren,1 Peng Wu,1 Liping Wang,1  
Mengjie Geng, Lingjia Zeng, Jun Zhang, 
Ningshao Xia, Shengjie Lai, Harry R. Dalton, 
Benjamin J. Cowling,2 Hongjie Yu2
We compared the epidemiology of hepatitis A and hepatitis 
E cases in China from 1990–2014 to better inform policy 
and prevention efforts. The incidence of hepatitis A cases 
declined dramatically, while hepatitis E incidence increased. 
During 2004–2014, hepatitis E mortality rates surpassed 
those of hepatitis A.
Hepatitis A virus (HAV) and hepatitis E virus (HEV) cause acute hepatitis in humans and are transmitted 
mainly through the fecal–oral route. Hepatitis A and hepa-
titis E became notifiable in China in 1990 and 1996, re-
spectively. Since the introduction of the hepatitis A vaccine 
and the start of mass vaccination in several countries in 
the 1980s, hepatitis A incidence declined substantially, not 
only among vaccinated children but in the population as 
whole (1,2). China first licensed its live attenuated hepatitis 
A vaccine in 1992 and later the inactivated hepatitis A vac-
cine in 2002 (3). The hepatitis A vaccine was initially in-
troduced into the private market, although some provinces 
provided subsidies through the World Health Organization 
Expanded Programme on Immunization (http://www.wpro.
who.int/china/areas/immunization/en/). Starting in May 
2008, hepatitis A vaccinations were incorporated into the 
routine national childhood immunization program for chil-
dren >18 months of age (3).
HEV is a substantial cause of illness and death world-
wide, particularly among pregnant women (4). Until the in-
troduction of the first hepatitis E vaccine to private markets 
in China in 2011, there were no specific pharmaceutical 
interventions for HEV (5). Given the similarity in diseases 
caused by HAV and HEV and the recent decline in hepati-
tis A incidence, we compared the epidemiology of human 
cases infected with the 2 pathogens in China.
The Study
We obtained data on cases of hepatitis A reported during 
1990–2014 and hepatitis E for 1997–2014 from China’s 
National Notifiable Disease Report System and collated de-
mographic information from the China National Bureau of 
Statistics. We defined confirmed cases on the basis of dates 
of disease onset and updated diagnostic criteria issued by 
the Chinese Ministry of Health in 2008; these critera are 
based on epidemiologic history, clinical signs, and labora-
tory test results (online Technical Appendix Table, https://
wwwnc.cdc.gov/EID/article/23/2/16-1095-Techapp1.pdf)
We used R version 3.0.1 (R Foundation for Statistical 
Computing, Vienna, Austria) and SAS version 9.2 (SAS 
Institute Inc., Cary, NC, USA) to estimate annual incidence 
and mortality rates for hepatitis A and hepatitis E according 
to patient age and sex. Notified cases were geocoded into 
provinces and mapped by ArcGIS 10 (Esri Inc., Redlands, 
CA, USA). To examine seasonality, we created heat maps 
by using monthly incidence normalized to the maximum 
incidence each year. We used a similar approach to ex-
amine seasonality across latitudes. We assessed potential 
associations between incidence and demographic and eco-
nomic factors by using Poisson regression.
Hepatitis A incidence dropped from 55.7 cases/100,000 
person-years in 1991 to 1.9 cases/100,000 person-years in 
2014, a decrease of 96.6% (Figure 1). In contrast, hepatitis E 
incidence increased significantly over this period, from 0.21 
cases/100,000 person-years in 1997 to 1.99 cases/100,000 
person-years in 2014, an 8-fold increase (p<0.0001 by 
Poisson regression) (Figure 1). The mortality and inci-
dence rates for hepatitis E overtook those for hepatitis A in 
2004 and 2011, respectively (Figure 1). Hepatitis E cases 
across the country were most frequently reported in March 
(online Technical Appendix Figures 4, 5). This change 
may result from increased temperature and rainfall in the 
spring, which could increase the likelihood of acquiring 
Changing Epidemiology of Hepatitis A and  
Hepatitis E Viruses in China, 1990–2014
Author affiliations: Key Laboratory of Surveillance and  
Early-Warning on Infectious Disease, Chinese Center for Disease 
Control and Prevention, Beijing, China (X. Ren, L. Wang,  
M. Geng, L. Zeng, S. Lai, H. Yu); World Health Organization  
Collaborating Centre for Infectious Disease Epidemiology and 
Control, Li Ka Shing Faculty of Medicine, The University of Hong 
Kong, Hong Kong, China (X. Ren, P. Wu, B. Cowling); State Key 
Laboratory of Molecular Vaccinology and Molecular Diagnostics, 
National Institute of Diagnostics and Vaccine Development in 
Infectious Diseases, Xiamen University School of Public Health, 
Xiamen, China (J. Zhang, N. Xia); University of Southampton, 
Southampton, UK (S. Lai); Royal Cornwall Hospital and European 
Centre for Environment and Human Health, University of Exeter, 
Truro, UK (H.R. Dalton); Fudan University School of Public Health, 
Key Laboratory of Public Health Safety, Ministry of Education, 
Shanghai, China (H. Yu)
DOI: http://dx.doi.org/10.3201/eid2302.161095
1These authors contributed equally to this article.
2These authors are joint senior authors. 
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 2, February 2017 277
HEV infection from exposure to contaminated water, such 
as water sourced from a stream near a free-range pig farm 
(6–8). In contrast, the seasonal pattern of HAV infections 
varied by latitude; cases were reported most frequently in 
the spring in southern provinces and in the autumn in most 
northern provinces (online Technical Appendix Figure 5). 
The decline in the incidence of hepatitis A cases in winter 
and summer varies by province, and reasons for the differ-
ential latitudinal pattern are unclear (7–9).
Hepatitis A incidence was highest among children and 
young adults (Figure 2). In contrast, hepatitis E incidence 
was highest among older adults and low among children 
and young adults (Figure 2). For both diseases, incidence 
and mortality rates were higher among male patients, and 
mortality rates tended to increase with age (Figure 2). The 
percentage of infections resulting in death were generally 
similar among men and women within each age group for 
most years (online Technical Appendix Figure 2).
We found considerable changes in the epidemiology 
of hepatitis A and E over time in mainland China. The 
major decline in hepatitis A incidence during 1992–2014 
cannot be explained solely by the introduction of the vac-
cine because implementation of vaccinations in the general 
population had been relatively low until the inactivated 
hepatitis A vaccine was included in the national Expanded 
Program on Immunization in May 2008 (3). Other key rea-
sons could be heightened public awareness, improved so-
cial hygiene, and upgrades in sewage treatment and water 
quality (9-11). Decreasing incidence was also accompanied 
by a change Hin the age distribution of reported hepatitis A 
case-patients; the average age increased over time (Figure 
2), possibly a consequence of inclusion of the vaccine in 
the national Expanded Program on Immunization, which 
targets children >18 months of age. The incidence of hepa-
titis A is now highest in northwestern China, which is a 
comparatively less developed region of the country (online 
Technical Appendix Figure 1).
Our findings in China are similar to those documented 
in other countries, where HEV infection is now more com-
mon than HAV infection (12,13). The increase in hepatitis 
E incidence could result from either a true increase in the 
number of cases or from improved case diagnosis.  Hepa-
titis E case-patients are mostly adults, particularly older 
adults (Figure 2). Although we did not have data on HEV 
genotypes for this study, it is possible that the change in 
age distribution of hepatitis E patients may result from the 
shift of the prevalent HEV genotype in China from geno-
type 1 to genotype 4 (and, to a lesser extent, genotype 3). 
Genotype 3 and genotype 4 are known to infect older men 
(14,15). The increase in the number of HEV infections in 
eastern China (online Technical Appendix Figure 1) could 
also be caused by this genotype shift and improved surveil-
lance in these more developed provinces (15), rather than 
by true geographic heterogeneity in risk factors. 
There are some limitations to our study (online Tech-
nical Appendix). Our findings are inferred from case no-
tification data, and the data quality could vary because 
of changes in case definitions. Other limitations include 
Figure 1. Annual incidence (solid lines) and mortality rates (dashed lines) of notified hepatitis A (blue) and E (red) cases in China, 1990–
2014. The inset shows an enlarged view of rates during 2009–2014. EPI, Expanded Program on Immunization; VLP, virus-like particle.
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variable availability of laboratory diagnostics and lack of 
hepatitis E genotype data. 
Conclusions
Reports of hepatitis A in China have declined substantially, 
while reports of hepatitis E cases have continued to rise. 
The mortality rate for hepatitis E surpassed that for hepa-
titis A in 2004. Decreasing trends of hepatitis A incidence 
after implementation of a vaccination program targeting 
children >18 months of age indicate a similar strategy for 
hepatitis E could be considered as a means to curtail inci-
dence. In addition, variations in demographic, geographic 
and seasonal distributions of hepatitis A and E may inform 
future prevention strategies in China.
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